8.45 0.00 (0.00%)
After hours: 7:58PM EST
|Bid||8.43 x 800|
|Ask||8.45 x 900|
|Day's Range||7.99 - 8.84|
|52 Week Range||5.12 - 15.30|
|Beta (3Y Monthly)||3.49|
|PE Ratio (TTM)||845.00|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors need to pay close attention to Cronos (CRON) stock based on the movements in the options market lately.
HENDERSON, NV / ACCESSWIRE / November 8, 2018 / Pot stocks have been on quite a roll recently, after Tuesday's election results yielded some great news for the sector, including Michigan legalizing recreational ...
Voters in Missouri approved Amendment 2 on Tuesday, making it the 31st state in the nation to adopt an effective medical marijuana law. Effective medical marijuana laws have now been adopted in 31 states, including Missouri, as well as in D.C. and the U.S. territories of Guam, Puerto Rico and the Northern Mariana Islands. Eighteen other states have adopted medical marijuana laws that are ineffective because they are either unworkable or exceptionally restrictive.
/ Healthcare stocks have been trending higher ahead of US midterm elections and now that the results are in, sector shares are rallying. Recent news across several marijuana stocks has shown this connection between healthcare and marijuana with several companies planning to expand into this industry and take advantage of its appeal in the medical community Today we're taking a closer look at 3 stocks in the space including Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI), Aphria (APHA) (APHQF) (APH) and Cronos Group (CRON) (CRON.TO). Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) announced this week that as a part of its expansion plans it will enter the Pharmacy market via acquisition and/or launching a new Canada based pharmacy in H1-2019.
HENDERSON, NV / ACCESSWIRE / November 7, 2018 / After a bit of a lull in the cannabis market, some of the top companies are on a roll again. We've highlighted the ones you should be paying attention to. ...
NEW YORK, NY / ACCESSWIRE / November 7, 2018 / Pot stocks continued on their tear on Tuesday with both Canopy Growth and Cronos Group seeing gains ahead of the United States midterm elections. Canopy closed ...
This is no Fox News hype about a caravan we're talking about here--it's the increasing number of Canadian cannabis stocks listing on American exchanges. Tilray(TLRY) has shot up from just around $22 per share at the beginning of 2018 to $300 very briefly. Sure, Tilray's market cap slid in late October and its founders dipped down below the billionaire threshold, but they probably aren't feeling too sorry for themselves.
CORAL GABLES, FL / ACCESSWIRE / November 6, 2018 / Marijuana stocks have seen a surge of attention this year. Canaccord analyst Bobby Burleson said in a research note, "We believe his year's midterms ...
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HENDERSON, NV / ACCESSWIRE / November 6, 2018 / As the stock market plummeted early October cannabis companies stayed strong, buoyed up by legislative changes in Canada. The cannabis market appears set ...
CORAL GABLES, FL / ACCESSWIRE / November 5, 2018 / The upcoming US midterm elections could be pivotal in progressing marijuana legalization. Additionally, if Jeff Sessions - who calls pot a "very real danger" and said "Good people don't smoke marijuana" - leaves, a more clear road to legalization is also a possibility. President Trump has publicly expressed his frustration over Sessions' decision to recuse himself from the investigation into whether the Trump campaign colluded with Russia in the 2016 presidential election.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cronos Group Inc. ("Cronos" or the "Company") (NASDAQ: CRON) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Specifically, Cronos’ distribution agreements with provinces of Canada were insignificant.